US 6200560B1
· Couto et al.
· 2001
[cited by applicant]
US 6936243B2
· Snyder et al.
· 2005
[cited by applicant]
US 7238346B2
· Vandendriessche et al.
· 2007
[cited by applicant]
US 9072722B2
· Fay et al.
· 2015
[cited by applicant]
US 9150847B2
· Rebar
· 2015
[cited by applicant]
US 20080019946A1
· Nenoi et al.
· 2008
[cited by applicant]
US 20200102577A1
· Lee et al.
· 2020
[cited by applicant]
US 20200237930A1
· Anguela
· 2020
[cited by examiner]
US 20230119850A1
· Riley et al.
· 2023
[cited by applicant]
CN 103917644A
· 2014
[cited by applicant]
CN 106456718A
· 2017
[cited by applicant]
CN 107531774A
· 2018
[cited by applicant]
CN 108093639A
· 2018
[cited by applicant]
EP 2451474B1
· 2013
[cited by applicant]
WO WO2005040384A1
· 2005
[cited by applicant]
WO WO2007021353A2
· 2007
[cited by applicant]
WO WO2009130208A1
· 2009
[cited by applicant]
WO WO2009134681A2
· 2009
[cited by examiner]
WO 2011005968A1
· 2011
[cited by applicant]
WO WO2013106787A1
· 2013
[cited by applicant]
WO WO2014043131A1
· 2014
[cited by applicant]
WO WO2014064277A1
· 2014
[cited by applicant]
WO WO2014162318A2
· 2014
[cited by applicant]
WO WO2015089046A1
· 2015
[cited by applicant]
WO WO2015089077A2
· 2015
[cited by applicant]
WO WO2017011519A1
· 2017
[cited by applicant]
WO WO2017053677A1
· 2017
[cited by applicant]
WO WO2017074526A1
· 2017
[cited by applicant]
George. Hemophilia gene therapy comes of age. Hematology Am Soc Hematol Educ Program. Dec. 8, 2017;2017(1):587-594. (Year: 2017).
[cited by examiner]
Leebeek et al. Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B. Blood (2016) 128 (22) : 2314. (Year: 2016).
[cited by examiner]
Rangarajan et al. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med . Dec. 28, 2017;377(26):2519-2530. Epub Dec. 9, 2017. (Year: 2017).
[cited by examiner]
Favaro et al. Safety of Liver Gene Transfer Following Peripheral Intravascular Delivery of Adeno-Associated Virus (AAV)-5 and AAV-6 in a Large Animal Model. Hum Gene Ther. Jul. 2011;22(7):843-52. Epub Mar. 8, 2011. (Yea…
[cited by examiner]
Chuah et al., “Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates,” Molecular Therapy (2014), vol. 22(9), pp. 1605-1613.
[cited by applicant]
Nair et al., “Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy,” Blood (2014), vol. 123(20), pp. 3195-3199.
[cited by applicant]
Haut et al., “Intron Definition Is Required for Excision of the Minute Virus of Mice Small Intron and Definition of the Upstream Exon,” Journal of Virol. (1998), vol. 72(3), pp. 1834-1843.
[cited by applicant]
Haut et al., “Inclusion of the NS2-Specific Exon in Minute Virus of Mice mRNA Is Facilitated by an Intronic Splicing Enhancer That Affects Definition of the Downstream Small Intron,” Virol. (1999), vol. 258(1), pp. 84-9…
[cited by applicant]
Kulkarni et al., “Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from the Centers for Disease Control and Prevention's …
[cited by applicant]
Shi et al., “Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A,” Journal of Thromb. and Haemost. (2007), vol. 5(2), pp. 352-361.
[cited by applicant]
Lee et al., “A New Potent hFIX Plasmid for Hemophilia B Gene Therapy,” Pharm. Res. (2004), vol. 21(7), pp. 1229-1232.
[cited by applicant]
Graham et al., “Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats,” Genet Vaccines Ther. (2008), vol. 6(9), 5 pages.
[cited by applicant]
Manno et al., “AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B,” Blood (2003), vol. 101(8), pp. 2963-2972.
[cited by applicant]
Manno et al., “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response,” NatureMedicine (2006), vol. 12(3), pp. 342-347.
[cited by applicant]
Nathwani et al., “Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins,” Mol. Ther. (2011), vol. 19(5), …
[cited by applicant]
Nathwani et al., “Adenovirus-associated virus vector-mediated gene transfer in hemophilia B,” N Engl J Med. (2011), vol. 365(25), pp. 2357-2365.
[cited by applicant]
Mcintosh et al., “Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant,” Blood (2013), 121(17), pp. 3335-3344.
[cited by applicant]
Wu, et al., “Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose,” Molecular Therapy (2008), vol. 16(2), pp. 280-289.
[cited by applicant]
Brown et al., “Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery,” Molecular Therapy—Methods & Clinical Development…
[cited by applicant]
Arruda et al., “Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy,” Molecular Therapy (2009), vol. 17(9), pp. 1492-1503.
[cited by applicant]
Ozawa, “Gene therapy using AAV vectors,” Drug Delivery System (2007), vol. 22(6), pp. 643-650.
[cited by applicant]
Mizukami, “Gene transfer method using AAV vectors,” Japanese Journal of Thrombosis and Hemostasis (2008), vol. 19(2), pp. 265-270.
[cited by applicant]
Bril et al., “Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg
[cited by applicant]
Chavez et al., “Long-Term Expression of Human Coagulation Factor VIII in a Tolerant Mouse Model Using the φ31 Integrase System,” Human Gene Therapy (2012), vol. 23, pp. 390-398.
[cited by applicant]
Costa et al., “Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region,” Nucleic Acids Research (1991…
[cited by applicant]
Donald et al., “Mutation of either G box or I box sequences profoundly affects expression from the
[cited by applicant]
Fagerlund et al., “The Cpf1 CRISPR-Cas protein expands genome-editing tools,” Genome Biology (2015), vol. 16:251, 3 pages.
[cited by applicant]
Gaj et al., “ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering,” Trends in Biotechnology (2013), vol. 37, No. 7, pp. 397-405.
[cited by applicant]
Guilinger et al., “Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification,” Nature Biotechnology (2014), vol. 32 No. 6, pp. 577-583.
[cited by applicant]
Ha et al., “Cis-acting regulatory elements controlling temporal and organ-specific activity of nopaline synthase promoter,” Nucleic Acids Research (1989), vol. 17 no., pp. 215-223.
[cited by applicant]
Johansen et al., “Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice—characterization of two novel FVIII molecules,” Haemophilia (2016), vol. 22(4), pp. 625-631.
[cited by applicant]
Kim et al., “A 20 nucleotide upstream element is essential for the nopaline synthase (nos) promoter activity,” Plant Molecular Biology (1994), vol. 24, pp. 105-117.
[cited by applicant]
Levinson et al., “A Transcribed Gene in an Intron of the Human Factor VIII Gene,” Genomics (1990), vol. 7(1), pp. 1-11.
[cited by applicant]
Li et al., “Human Enhancers Are Fragile and Prone to Deactivating Mutations,” Mol. Biol. Evol. (2015), vol. 32(8), pp. 2161-2180.
[cited by applicant]
Ljung, “Prophylactic Infusion Regimens in the Management of Hemophilia,” Thrombosis and Haemostasis (1999), vol. 82(2), pp. 525-530.
[cited by applicant]
McCaffrey et al., CRISPR-CAS9 D10A nickase target-specific fluorescent labeling of double strand DNA for whole genome mapping and structural variation analysis, Nucleic Acids Research (2016), vol. 44, No. 2, 8 pages.
[cited by applicant]
Niu et al., “Applications of TALENs and CRISPR/Cas9 in Human Cells and Their Potentials for Gene Therapy,” Mol. Biotechnol. (2014), vol. 56, pp. 681-688.
[cited by applicant]
Osorio et al., “Role of dendritic cells in the induction of lymphocyte tolerance,” Front. Immunol. (2015), vol. 6, article 535, 11 pages.
[cited by applicant]
Raker et al., “Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man,” Front. Immunol., (2015), vol. 6, article 569, 11 pages.
[cited by applicant]
Scott et al., “Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation,” British Journal of Haematology (2011), vol. 156(3), pp. 295-302.
[cited by applicant]
Wang et al., “Hepatocyte nuclear factor-4α interacts with other hepatocyte nuclear factors in regulating transthyretin gene expression,” Fees J. (2010), vol. 277(19), pp. 4066-4075.
[cited by applicant]
Jiang et al., “Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs,” 2006, Blood, 108 (1): 107-115, https://doi.org/10.11.
[cited by applicant]
Office Action issued for the Chinese Patent Application No. 201980051349.9 issued on May 31, 2024, 17 pages.
[cited by applicant]
Examination Report and Search Report issued for the United Arab Emirates patent Application No. P600121/2021 dated Sep. 6, 2024, 8 pages.
[cited by applicant]
Au et al. (2022) “Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings” Front. Med. 8:809118 doi: 10.3389/fmed.2021.809118, 14 pages.
[cited by applicant]
Issa et al. (2023) “Various AAV Serotypes and Their Applications in Gene Therapy: An Overview” Cells 12:785 https://doi.org/10.3390/cells12050785, 41 pages.
[cited by applicant]
Substantive Examination Report issued for Saudi Arabian Patent Application No. 521421111 on Aug. 19, 2025, 10 pages.
[cited by applicant]